Navigation Links
ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference
Date:2/9/2009

Demonstrating the Clinical and Economic Value of Pharmaceuticals in a New U.S. Political Administration

PHILADELPHIA, Feb. 9 /PRNewswire/ -- ExL Pharma today announced the start of the first annual conference on Managed Markets Insight & Marketing for the Pharmaceutical Industry at the Loews Philadelphia Hotel. The conference will provide managed markets marketers with strategic insights needed to prepare for future changes in health care, and to be informed regarding potential strategies to consider when developing biopharmaceutical value propositions for payers.

With a new political administration expected to address healthcare policy issues and expand federal government involvement in healthcare, including potentially direct drug price negotiation, the two-day conference will feature industry leaders and other experts on key topics including consumerism, Medicare Part D, and potential implications for managed markets marketing professionals to consider based upon stated policy positions being debated by the 111th Congress and the new Obama presidential administration.

The keynote speaker, Stan Bernard, MD, MBA, president, Bernard Communications, will comment on the future of pharma. Bernard will focus on understanding the implications and applications of U.S. Pharma's transition to a mature industry for managed markets marketing.

Douglas Jordan, senior vice president and managed markets practice leader, Euro RSCG Life, will be discussing insights and strategies to help ensure marketers successfully address the emerging needs of a diverse and evolving healthcare stakeholder group.

Key components of Jordan's presentation include the application of Customer Relationship Marketing (CRM) in the managed markets environment, and development of fully integrated programs that apply innovation and technology to meet the diverse needs and target audiences biopharmaceutical manufacturers seek to engage across all payor channels.

"There are many issues and challenges biopharmaceutical marketers need to consider in today's dynamic marketplace," Jordan said. "More than ever, brand marketers must establish a clear and compelling Value Proposition for payer decision makers that supports brand positioning, and achieves favorable access and reimbursement on public and private payer formularies."

For additional information on the conference or to arrange an interview, contact Carrie Yamond at 212-367-6943 or Carrie.yamond@eurorscg.com.

About ExL Pharma:

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.

About Euro RSCG Life:

Euro RSCG Life aligns the company's 50 health-focused offices in 30 countries. It creates a single network with over 1,500 employees offering clients comprehensive communications disciplines, including advertising, public relations, event promotion, medical education, digital marketing, direct to patient and consulting services. The network's client roster includes GlaxoSmithKline, Novartis, Pfizer, sanofi-aventis, Schering-Plough and Wyeth. Euro RSCG Life is part of Euro RSCG Worldwide, a leading global marketing communications agency, and the largest unit of Havas, the world's fourth-largest communications group (Euronext Paris SA: HAV.Pa).

    CONTACT:
    Carrie Yamond
    Euro RSCG Life PR
    (212) 367-6943
    Carrie.yamond@eurorscg.com


'/>"/>
SOURCE Euro RSCG Life
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
Breaking Biology News(10 mins):